AnaptysBio 過去の業績
過去 基準チェック /06
AnaptysBioの収益は年間平均-23%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間19% 5.6%割合で 減少しています。
主要情報
-23.0%
収益成長率
-22.8%
EPS成長率
Biotechs 業界の成長 | 17.0% |
収益成長率 | -5.6% |
株主資本利益率 | -1,722.0% |
ネット・マージン | -558.2% |
前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs
Nov 01AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point
Aug 15AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)
Jul 08News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
May 22Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates
May 12Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?
Feb 22Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Oct 10AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 24Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?
Apr 27Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Jan 10AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial
Oct 05Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher
Sep 14AnaptysBio sells royalties from GSK-partnered Zejula for $45M
Sep 12AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans
Sep 01AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%
Aug 31AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M
Aug 08Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates
May 10Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Mar 16AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest
Nov 11AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business
Jul 28Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
May 09AnaptysBio EPS beats by $0.03, beats on revenue
May 04収支内訳
収支内訳
AnaptysBio の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 24 | 30 | -170 | 42 | 0 |
31 Mar 24 | 23 | -163 | 43 | 0 |
31 Dec 23 | 17 | -164 | 42 | 0 |
30 Sep 23 | 15 | -148 | 41 | 0 |
30 Jun 23 | 13 | -144 | 37 | 0 |
31 Mar 23 | 11 | -137 | 37 | 0 |
31 Dec 22 | 10 | -129 | 33 | 0 |
30 Sep 22 | 4 | -135 | 29 | 0 |
30 Jun 22 | 24 | -108 | 29 | 0 |
31 Mar 22 | 53 | -76 | 23 | 0 |
31 Dec 21 | 63 | -58 | 21 | 0 |
30 Sep 21 | 122 | 8 | 21 | 0 |
30 Jun 21 | 101 | -9 | 21 | 0 |
31 Mar 21 | 71 | -30 | 20 | 0 |
31 Dec 20 | 75 | -20 | 19 | 0 |
30 Sep 20 | 18 | -74 | 18 | 0 |
30 Jun 20 | 18 | -81 | 17 | 0 |
31 Mar 20 | 23 | -84 | 16 | 0 |
31 Dec 19 | 8 | -97 | 16 | 0 |
30 Sep 19 | 5 | -94 | 16 | 0 |
30 Jun 19 | 10 | -79 | 16 | 0 |
31 Mar 19 | 5 | -69 | 16 | 0 |
31 Dec 18 | 5 | -62 | 16 | 0 |
30 Sep 18 | 8 | -52 | 14 | 0 |
30 Jun 18 | 3 | -45 | 13 | 0 |
31 Mar 18 | 10 | -34 | 11 | 0 |
31 Dec 17 | 10 | -30 | 9 | 0 |
30 Sep 17 | 10 | -27 | 8 | 0 |
30 Jun 17 | 13 | -19 | 6 | 0 |
31 Mar 17 | 12 | -15 | 5 | 0 |
31 Dec 16 | 17 | -4 | 4 | 0 |
30 Sep 16 | 18 | -4 | 4 | 0 |
30 Jun 16 | 19 | -4 | 4 | 0 |
31 Mar 16 | 18 | -6 | 4 | 0 |
31 Dec 15 | 18 | -5 | 4 | 0 |
30 Sep 15 | 17 | -2 | 3 | 0 |
30 Jun 15 | 19 | 0 | 3 | 0 |
31 Mar 15 | 18 | 1 | 3 | 0 |
31 Dec 14 | 16 | 0 | 2 | 0 |
31 Dec 13 | 5 | -6 | 2 | 0 |
質の高い収益: ANABは現在利益が出ていません。
利益率の向上: ANABは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: ANABは利益が出ておらず、過去 5 年間で損失は年間23%の割合で増加しています。
成長の加速: ANABの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: ANABは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -2.3% ) と比較することは困難です。
株主資本利益率
高いROE: ANABは現在利益が出ていないため、自己資本利益率 ( -1721.99% ) はマイナスです。